Last reviewed · How we verify

NCT06713785: PERSONAL HTN

Personalised Electronic Record Supported Optimisation of Amlodipine for Patients With Hypertension

Withdrawn Phase 4 Last updated 3 December 2024
What this trial tests

Phase 4 trial testing Amlodipine in Hypertension. Withdrawn.

Timeline
26 September 2020
Primary endpoint
31 January 2021
31 May 2021

Quick facts

Lead sponsorQueen Mary University of London
PhasePhase 4
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationnon randomized
Designsingle group
Maskingnone
Primary purposetreatment
Start date26 September 2020
Primary completion31 January 2021
Estimated completion31 May 2021

Drugs / interventions tested

Conditions studied

Sponsor

Queen Mary University of London

Who can join

Adults 18 to 75, any sex, with Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of the study is to assess precision dosing of amlodipine to deliver reductions in blood pressure in patients with primary hypertension and inadequate BP control by up-titration of amlodipine in 1mg increments

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Amlodipine

Trials testing the same drug.

Other recruiting trials for Hypertension

Currently open trials in the same condition.

Other Queen Mary University of London trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06713785.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing